Home
About
Overview
Sharing Data
ORCID
Help
History (49)
Sauer, Kevin
Silanes
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Activated factor VII levels in patients with angiographically confirmed coronary artery disease.
IL-17 contributes to the development of chronic rejection in a murine heart transplant model.
See All 49 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
IL-17 contributes to the development of chronic rejection in a murine heart transplant model.
IL-17 contributes to the development of chronic rejection in a murine heart transplant model. J Clin Immunol. 2010 Mar; 30(2):235-40.
View in:
PubMed
subject areas
Animals
Antigens, CD
Cell Separation
Cells, Cultured
Chronic Disease
Flow Cytometry
Graft Occlusion, Vascular
Graft Rejection
Heart Transplantation
Interleukin-17
Mice
Mice, Inbred C57BL
Mice, Knockout
Mice, Mutant Strains
Myocardium
Receptors, Antigen, T-Cell, gamma-delta
T-Lymphocyte Subsets
T-Lymphocytes
authors with profiles
Robert Axtell